The primary objective was to evaluate safety and tolerability of Ropanicant in patients with MDD
First-in-human Phase-1 study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SUVN-I6107 in healthy subjects
Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors
Sanofi India has reported total income of Rs. 738.9 crores during the period ended March 31, 2024
This approval helps address an urgent unmet need, with about half of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy
Global Phase-3 study initiation expected in the second half of 2024
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
Utidelone has the ability to cross BBB due to its unique physicochemical characteristic and insusceptibility to P-glycoprotein-mediated efflux
Cipla will be responsible for the distribution of Sanofi India's six CNS brands including Frisium
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
Subscribe To Our Newsletter & Stay Updated
